Compare Firy Inc. (FIRY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs TG Therapeutics Inc — how do they compare? Firy Inc. trades at $12.07 (market cap $199.80M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 40.8× Firy Inc.'s market cap, and Firy Inc. is more actively traded (92,993 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and TG Therapeutics Inc for 16 Days on average.
| FIRY | TGTX | |
|---|---|---|
Market Cap | $199.80M | $8.16B |
Volume | 92,993 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $13.10 | $59.06 |
52-Week Low | $2.28 | $26.94 |
Typical Hold Time | 13 Days | 16 Days |
Enterprise Value | $168.40M | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY trades at $12.02, up 1.43% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0M but missed EPS expectations with a net loss. Recent developments include a $719M legal victory and board appointment of Marc Lasry. Despite high gross margins of 87.76%, the company shows negative profitability metrics with ROE at -62.95% and persistent cash burn.
The outlook remains challenged by ongoing losses and cash flow deficits, though the legal win provides potential upside. Analyst sentiment is mixed with 60% hold ratings. Key risks include execution on collections and sustainable revenue growth. The stock presents speculative potential but requires careful risk assessment given fundamental weaknesses.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
